# A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation

- Link: https://www.thailand-business-news.com/pr-news/a-defining-milestone-for-gene-solutions-spot-mas-multi-cancer-screening-test-receives-u-s-fda-breakthrough-device-designation
- Published: 2026-07-22T08:00:00+07:00
- Author: Media OutReach

HONG KONG SAR – [Media OutReach Newswire](https://www.media-outreach.com/) – 22 
July 2026 – Gene Solutions – a global biotechnology company advancing accessible
genomic solutions for cancer detection and precision oncology, announced that **
SPOT-MAS 10** has received **Breakthrough Device Designation from the U.S. Food 
and Drug Administration (FDA)**. This designation marks an important regulatory 
milestone for Gene Solutions and reflects the continued progress of SPOT-MAS as 
an AI-powered, multi-omic platform for early cancer detection.

![SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation](
https://images.media-outreach.com/788909/image_1.jpeg)

 _SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation_

 The proposed indications for use describe **SPOT-MAS 10** as a qualitative in vitro
diagnostic test performed on plasma derived from a single direct-draw venous whole
blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic
signatures using a machine-learning-based algorithm to detect a cancer-associated
signal. It is intended for use as an **adjunctive screening test in asymptomatic
adults aged 40 years and older** to assist in detecting cancers within the scope
of the assay. These include five common cancers — **breast, lung, liver, colorectal
and gastric cancers** — and five aggressive, less common cancers that currently 
lack standard screening methods — **ovarian, pancreatic, esophageal, endometrial
and head & neck cancers**.

 SPOT-MAS has been developed through years of rigorous scientific research and clinical
development. In March 2025, SPOT-MAS became the first multi-cancer screening blood
test in Asia to complete a large prospective cohort validation, with the K-DETEK
study evaluating more than 9,000 asymptomatic participants and demonstrating strong
performance, including high specificity and the ability to identify cancer-associated
signals across multiple cancer types.

 Since then, SPOT-MAS has been used in more than **100,000 individuals** in real-
world practice, with consistent performance observed beyond controlled study settings.
Real-world data were presented at **ESMO Asia 2025 **and were featured at **ASCO
Breakthrough 2026 **in Singapore.

 The platform is built on a multi-omic approach— integrating genetics, epigenetics,
and fragmentomics — together with AI-driven analysis, large-scale prospective validation,
growing real-world evidence and focus on cancer types with high clinical relevance
in the regions where the test is deployed.

 For the United States, Breakthrough Device Designation provides Gene Solutions 
with a prioritized channel of engagement with the FDA as the company advances its
U.S. development and validation plans.

 Looking ahead, Gene Solutions will continue to collaborate with academic, clinical,
laboratory, commercial and strategic partners to support responsible adoption of
SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.

 **Important Regulatory Notice:** SPOT-MAS 10 has received U.S. FDA Breakthrough
Device Designation. Breakthrough Device Designation is not FDA approval, clearance
or marketing authorization. The device remains subject to applicable FDA regulatory
review requirements, and the designation does not guarantee future FDA approval,
clearance or authorization.

 For more information, visit https://spotmas.com.hk

 Contact: 
 [hk.cs@genesolutions.com](https://www.thailand-business-news.com/pr-news/hk.cs@genesolutions.com)
Source: Gene Solutions Hong Kong Limited.  SPOTMAS_062026_04

Hashtag: #SPOTMAS

[https://spotmas.com.hk/](https://spotmas.com.hk/)

The issuer is solely responsible for the content of this announcement.

![](//track.media-outreach.com/index.php/WebView/474231/36955)

**Source** : [A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation](https://www.media-outreach.com/news/hong-kong-sar/2026/07/22/474231/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)